See More. Treat Better. Reduce Recurrence.

Bladder cancer affects over 3 million people worldwide1 and has one of the highest recurrence rates — up to 70% after initial transurethral resection of bladder tumor (TURBT)2 — making it one of the most costly and burdensome cancers to manage.​

Olympus aims to reduce bladder cancer recurrence through improved detection and resection of NMIBC tumors, enhancing health outcomes and patient experiences.

Why Choose Olympus?

  • See What Others Miss — 4K imaging, Narrow Band Imaging (NBI) and blue light technology (BL) for cystoscopy to enhance lesion detection.
  • Resect with Confidence — PLASMA+ bipolar resection system for precise and controlled tumor removal.
  • Innovate Every Step — VISERA S for outpatient detection and follow-up and 4K pendulum camera head for high-resolution surgeries.

Scroll further to experience the future of NMIBC care.

Our NMIBC Portfolio — Optimized for Every Stage of the Patient Journey


Detect tumors with greater clarity and confidence using imaging solutions from Olympus.

VISERA ELITE III — 4K imaging for exceptional mucosal detail.​

Narrow Band Imaging (NBI) — NBI visualizes 28% more carcinomas in situ (cis) compared to white light (WL) imaging.5

Blue Light Technology — Fluorescence-guided resection is more sensitive for detecting malignant tumors compared to white-light procedures.​

Flexible Video Cystoscopes — Optimized for patient comfort and high-resolution imaging.

Learn more about our visualization solutions

Achieve safer, more precise tumor removal with the advanced resection technology from Olympus.​

PLASMA+ Powered by New ESG-410 Surgical Energy Platform — Offers stable and fast ignition even in free saline, ensuring controlled tumor removal.

OES Pro Resectoscope — Designed for ergonomic control and procedural efficiency.​

4K NBI for Surgery — Enhances vascularity and mucosal patterns to support surgical precision.​

Explore our resection solutions

Monitor patient outcomes and reduce recurrence risk with long-term Olympus solutions.​

VISERA S — Enables seamless documentation from diagnosis to follow-up.​

NBI for Surveillance — Leads to a 37% lower likelihood of recurrence over 12-15 months.6​

Olympus Continuum Training and Service — Supporting surgeons with education, maintenance, and workflow optimization.

Find out how we support long-term patient care

Voices From the Field: How Experts Use NBI to Improve Diagnosis and Care in NMIBC

Request a Demo — See the Difference

Discover how Olympus NMIBC solutions enhance detection, precision and patient outcomes.

Expert Insights and Real-World Impact

Surgeon testimonials: Leading urologists share how Olympus technology enhances NMIBC procedures.

  • NBI Helps Discount the Suspicion of Malignancy Raised during White Light Cystoscopy
  • NBI Confirms Papillomatosis
  • NBI Cystoscopy – Ta lesions - HG Ta Visualized by NBI in Follow-Up Cystoscopy
  • NBI Cystoscopy – Ta lesions - Extremely Clear Visualization of LG Ta Lesion
  • Transurethral PLASMA En-bloc Resection of NMIBC

Related Products

Products - Filter by

Discover Sharper Cancer Detection with NBI in Urology

Unlock the power of enhanced visual clarity. NBI elevates urological diagnostics by improving visibility of bladder tumors and suspicious lesions — helping clinicians detect cancer with greater precision and confidence.

Explore the NBI Advantage in Urology

Downloads

NMIBC eBrochure (PDF, 32.7 MB)

NMIBC Infographic (PDF, 4.0 MB)

References
1. Zi H, Liu MY, Luo LS, et al. Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021. Mil Med Res. 2024;11(1):64. doi:10.1186/s40779-024-00569- w​
2. Holzbeierlein JM, Bixler BR, Buckley DI, et al. Diagnosis and Treatment of Non- Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment published correction appears in J Urol. 2024 Dec;212(6):936. doi:10.1097/JU.0000000000004251.]. J Urol. 2024;211(4):533-538.doi:10.1097/JU.000000000000384​
3. Fan Z, Shi H, Luo J, et al. Diagnostic and therapeutic effects of fluorescence cystoscopy and narrow-band imaging in bladder cancer: a systematic review and network meta-analysis. Int J Surg. 2023;109(10):3169-3177. Published 2023 Oct 1. doi:10.1097/JS9.0000000000000592​
4. Oserowsky A, Anwar T, Lough C, Golzy M, Murray KS. The Significant Role of Depression in Elderly Patients with Bladder Cancer. Eur Urol Open Sci. 2021;33:11-18. Published 2021 Sep 22. doi:10.1016/j.euros.2021.08.007​
5. Li et al., Diagnosis of narrow-band imaging in non-muscle-invasive bladder cancer: A systematic review and meta-analysis, International Journal of Urology 2013; 20:602–609.​
6 Lai LY, Tafuri SM, Ginier EC, et al. Narrow band imaging versus white light cystoscopy alone for transurethral resection of non-muscle invasive bladder cancer. Cochrane Database Syst Rev. 2022;4(4):CD014887.​ Published 2022 Apr 8. doi:10.1002/14651858. CD014887.pub2